On August 25, the National Health Commission held a press conference in Beijing
.
In terms of paediatric drugs, Jiang Jiandong, academician of the Chinese Academy of Engineering and president of the Institute of Materia Medica of the Chinese Academy of Medical Sciences, introduced that 47 paediatric drugs will be approved for marketing in 2021, which will significantly improve the level of clinical paediatric drugs
.
The National Health and Health Commission stated that the country attaches great importance to the shortage of children's medicines, and specially organized a special research and development project for children's medicines, and invested more than 600 million yuan through major special projects for new drug creation to research children's medicines
.
Research plans for 105 drugs have been announced in three batches
.
The National Health Commission has established the National Children's Medical Center, organized 23 national pediatric-related units, and established the "Chinese Pediatric Population Drug Clinical Trial Collaboration Network" to promote drug clinical research
.
In recent years, the National Health and Health Commission, the State Food and Drug Administration, the Ministry of Industry and Information Technology, the National Medical Insurance Administration and other departments have also jointly promoted the research and development and production of children's medicines
.
Children's medication is different from adults.
Generally speaking, there is still a shortage of special medicines for children in China.
However, under the strong promotion of national policies in recent years, the level of children's medication in China has been significantly improved
.
Industry insiders said that in the past, the research and development of special medicines for children had high risks, high investment and low returns, resulting in fewer varieties and specifications of children's medicines in China; now, with policy support and market demand, the children's medicine market with insufficient supply is expected to usher in rapid growth.
development period
.
Before that, the State Food and Drug Administration also stated that it will give priority to the review and approval of pediatric medicines with clinical value and urgent needs of patients, open a green channel for children's medicines, take the initiative to serve R&D enterprises in the front, and conduct communication, acceptance, and evaluation of enterprises.
Actively provide services in other links, improve the efficiency of variety processing, minimize the review time, and promote the accelerated review and listing of children's drugs
.
According to data, from January to April 2022, the Drug Evaluation Center of the State Food and Drug Administration has completed 30 technical review tasks for children's drug use, a year-on-year increase of 91%
.
The industry predicts that, driven by favorable policies, new and old children's pharmaceutical companies will have the opportunity to usher in a golden period of development
.
Taking Sunflower Pharmaceutical as an example, in the first half of this year, the company achieved an operating income of 2.
249 billion yuan, a year-on-year increase of 7.
01%.
Among them, the core main product of children's medicine, children's lung fever, maintained a healthy growth
.
It is understood that Sunflower Pharmaceutical's children's respiratory disease drug sector gathers the company's major single product categories.
At present, there are honeysuckle dew, Xiaoer Chaigui Ture Granules, Xiaoer Paracetamol Huangnamin Granules, and Xiaoer Feirekechuan Oral Liquid The sales of many children's medicines such as / granules and amoxicillin granules exceeded 100 million
.
In addition, driven by favorable national policies, pharmaceutical companies are expected to increase the distribution of children's drug pipelines and accelerate clinical research covering children-related indications
.
Among them, the above-mentioned Sunflower Pharmaceuticals has been active in the field of children's medicine.
In addition, Jichuan, Dain, Jianmin, etc.
, including Hengrui Medicine, Yiling Pharmaceutical and other large pharmaceutical companies are expanding their own drug indications to children Indications, and a batch of new Biotechs such as Tianjing Bio, Xianweida Bio, Aike Baifa, Weisheng Pharmaceutical, Baitai Bio, and Beimei Pharmaceutical participated in it in various forms
.
According to Jiang Jiandong, under the promotion of policies, China's children's drug use situation has improved significantly
.
For example, recombinant human factor VIII for the treatment of juvenile hemophilia A, propranolol for the treatment of childhood hemangiomas, and chloral hydrate/syrup, a commonly used drug for children, have been approved for marketing
.
Over the past few years, children have been in desperate need of medicines on the market
.
In 2021, a total of 47 children's medicines have been approved for marketing nationwide, 14 of which have been included in the priority review and approval process, and the marketing process of children's medicines has been greatly promoted
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
